PRIDE. Assessment of the Efficacy, Adherence and Tolerability of the Single Pill Combination Bisoprolol/Perindopril
단계 해당 없음
완료
NCT04656847
| 대상 질환 | Coronary Artery Disease, Myocardial Infarction, Arterial Hypertension |
|---|
| 임상 단계 | 단계 해당 없음 |
|---|
| 스폰서 | Servier Russia |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 504 명 |
|---|
| 중재(약물) | in daily everyday routine practice |
|---|
| 시작일 | 2021년 3월 1일 |
|---|
| 완료일 | 2021년 10월 5일 |
|---|
| 결과 공개일 | 2024년 11월 1일 |
|---|
요약
This non-interventional, ambispective study was aimed at evaluating the effectiveness, safety, and tolerability of bisoprolol and perindopril SPC in previous myocardial infarction patients with HTN and CAD treated with the drug for 12 weeks in the daily clinical practice. SPC will be used according to the approved instruction for medical use of the medicine. This is a multi-centre, observational, incomparative, ambispective study, which will retrospectively and prospectively collect clinical variables and socio-demographic data from medical records of patients with HTN and previous MI initiated with bisoprolol/perindopril SPC in real life settings.
Antihypertensive Effectiveness (SBP and DBP) of Bisoprolol/Perindopril SPC in CAD Patients With Previous MI and HTN at Week 12 of Treatment Compared With Baseline
3 months · mm Hg
| CAD Patients With Previous MI and HTN | -24.92 ± 16.43 mm Hg |
|---|
| CAD Patients With Previous MI and HTN | -12.21 ± 11.03 mm Hg |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.